Turning cancer defects into cures

With a team of 70 scientists from 22 different nations we turn cancer defects into novel treatments. Subscribe to our newsletter to stay updated and donate to support our laboratory!

Donate

Thomas Helleday receives SYNTRAIN grant

Thomas Helledays receives ERC Advanced Grant

Thomas Helledays receives ERC Advanced Grant Thomas Helleday is one of nine scientists receiving a grant of 2.5 million euros over five years from the European Research Council. Research proposed for funding to the ERC should aim high, both with regards to the...

Lynparza™ (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer

Nina Gustafsson Sheppard gets a 100000 SEK grant from KI funds – Felix Mindus bidrag till leukemiforskningen!

Welcome to our website!

We proudly present a completely novel way of treating cancer, which has been published in Nature. The new concept exploits the high level of oxidative stress present within cancer that is absent in healthy cells. Oxidative stress can damage the building blocks of DNA, and the use of these damaged building blocks in DNA synthesis can cause cell death. The MTH1 protein protects cancer cells from this, and thus we aim to inhibit the MTH1 protein to specifically kill cancer cells.

Read more


News

When and why MTH1?

When and why MTH1? A new study lead by scientists from the Helleday laboratory at Karolinska Institutet together with colleagues from Stockholms University and the Heinrich-Heine University in Duesseldorf have now shed light on that question. Since the break-through...

Mary-Claire King visits Helleday Laboratory

Mary-Claire King visits Helleday Laboratory Lasker award winner, Nobel Peace Prize nominee and discoverer of BRCA1 Mary-Claire King visited Stockholm to give a Nobel Forum lecture. Mary-Claire King, PhD, is American Cancer Society Professor at the University of...

“I am naturally happy and impressed by your work. Words can not describe how grateful I am; not only for my sake but for my children and family as well. It gives me hope to break the chain of cancer in the family. I hope for the drug to reach the market soon so more can be treated.” Translated from Swedish

Marie

Stockholm

Our vision

We believe our treatments will be turning cancer into a chronic disease and that we will be able to provide affordable treatments across the world. We reach our goal through open innovation and through a foundation, ensuring long term benefit to mankind.

Our mission

We turn cancer defects into novel treatments. Cancer cells already have a lot of DNA damage and disrupted DNA repair. By inhibiting DNA repair we increase the DNA damage to kill cancer cells, without harming healthy cells.